By Miss Emma Zahra

Journal articles

McKetin R; Degan TJ; Saunders L; Nguyen L; Dore G; Shoptaw S; Farrell M; Degenhardt L; Kelly PJ; Turner A; Clare PJ; Dean OM; Arunogiri S; Colledge-Frisby S; Koeijers J; Goodman-Meza D; Sinclair B; Reid D; Hill H; Hayllar J; Christmass M; Cordaro F; Lundin R; Liaw W; Liu D; Holyoak E; Wu BTF; Keygan J; Kontogiannis A; Palmer L; Morrison C; Wrobel A; Hyland B; Byrne M; Russell S; Zahra E; Berk M, 2024, 'A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial', Trials, 25, http://dx.doi.org/10.1186/s13063-024-08238-y

Zahra E; Darke S; Lappin J; Duflou J; Farrell M, 2024, 'Baclofen-related deaths in Australia 2000–2022', Forensic Science International, 365, http://dx.doi.org/10.1016/j.forsciint.2024.112281

Farrell M; Shahbazi J; Chambers M; Byrne M; Gholami J; Zahra E; Grebely J; Lintzeris N; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Weiss R; Rodgers C; Cook J; Degenhardt L, 2024, '96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104390

Degenhardt L; Clark B; Macpherson G; Leppan O; Nielsen S; Zahra E; Larance B; Kimber J; Martino-Burke D; Hickman M; Farrell M, 2023, 'Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies', The Lancet Psychiatry, 10, pp. 386 - 402, http://dx.doi.org/10.1016/S2215-0366(23)00095-0

Darke S; Zahra E; Duflou J; Peacock A; Farrell M; Lappin J, 2023, 'Characteristics and circumstances of volatile solvent misuse-related death in Australia, 2000–2021', Clinical Toxicology, 61, pp. 260 - 265, http://dx.doi.org/10.1080/15563650.2023.2184243

Lappin JM; Zahra E; Darke S; Shand F; Sharma S; Draper B; Connors MH; Dear B; Titov N; Campbell G, 2022, 'Presentations to the emergency department with self-harm or suicidal behaviours: A role for digital mental health services?', Journal of Psychiatric Research, 154, pp. 50 - 55, http://dx.doi.org/10.1016/j.jpsychires.2022.07.046

Zahra E; Chen R; Nielsen S; Tran AD; Santo T; Degenhardt L; Farrell M; Byrne J; Ali R; Larance B, 2022, 'Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients', Drug and Alcohol Review, 41, pp. 841 - 850, http://dx.doi.org/10.1111/dar.13437

Darke S; Chrzanowska A; Campbell G; Zahra E; Lappin J, 2022, 'Barbiturate-related hospitalisations, drug treatment episodes, and deaths in Australia, 2000‒2018', Medical Journal of Australia, 216, pp. 194 - 198, http://dx.doi.org/10.5694/mja2.51306

Weatherburn D; Darke S; Zahra E; Farrell M, 2022, 'Who would try (or use more) cannabis if it were legal?', Drug and Alcohol Review, 41, pp. 386 - 395, http://dx.doi.org/10.1111/dar.13360

Tran AD; Chen R; Nielsen S; Zahra E; Degenhardt L; Santo T; Farrell M; Larance B, 2022, 'Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions', International Journal of Drug Policy, 99, http://dx.doi.org/10.1016/j.drugpo.2021.103472

Campbell G; Darke S; Zahra E; Duflou J; Shand F; Lappin J, 2021, 'Trends and characteristics in barbiturate deaths Australia 2000-2019: a national retrospective study', Clinical toxicology (Philadelphia, Pa.), 59, pp. 224 - 230, http://dx.doi.org/10.1080/15563650.2020.1789653

Zahra E; Darke S; Degenhardt L; Campbell G, 2020, 'Rates, characteristics and manner of cannabis-related deaths in Australia 2000–2018', Drug and Alcohol Dependence, 212, http://dx.doi.org/10.1016/j.drugalcdep.2020.108028

Conference Papers

Lappin J; Campbell G; Darke S; Zahra E; Dear B; Titov N, 2021, 'ONLINE INTERVENTIONS FOR SUICIDAL BEHAVIOURS IN THE EMERGENCY DEPARTMENT', in AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, SAGE PUBLICATIONS LTD, pp. 91 - 91, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000648619900212&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Reports

Shahbazi J; Farrell M; Byrne J; Ali R; Puszka B; Lim XQ; Cook J; Weiss R; Rodgers C; Dunlop A; Lintzeris N; Nielsen S; Grebely J; Zahra E; Degenhardt L; Byrne M, 2023, Considerations for delivering extended-release buprenorphine for opioid dependence in Australia: Preliminary lessons from the Community Long-Acting Buprenorphine (CoLAB) trial, NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, 2020, RANDWICK, 355, http://dx.doi.org/10.26190/zemp-dx93

Whetton S; Tait RJ; Chrzanowska A; Donnelly N; McEntee A; Mukhtar A; Zahra E; Campbell G; Degenhardt L; Dey T; Halim SA; Hall W; Makate M; Norman R; Peacock A; Roche A; Allsop S, 2020, Quantifying the Social Costs of Cannabis Use to Australia in 2015/16, NDRI, T287, https://ndri.curtin.edu.au/ndri/media/documents/publications/T287.pdf

Whetton S; Robert J. T; Chrzanowska A; Neil D; McEntee A; Mukhtar A; Zahra E; Campbell G; Degenhardt L; Dey T; Abdul Halim S; Hall W; Makate M; Norman R; Peacock A; Roche A; Allsop S, 2020, Quantifying the Social Costs of Pharmaceutical Opioid Misuse & Illicit Opioid Use to Australia in 2015/16, NDRI, http://nceta.flinders.edu.au/files/7215/8985/7311/Quantifying_the_Social_Costs_of_Pharmaceutical_Opioid_Misuse_and_Illicit_Opioid_Use_to_Australia_in_2015-16.pdf

Back to profile page